Brief: Nuvation Bio To Expand Pivotal Phase 3 Sigma Study Of Safusidenib For Idh1-Mutant Glioma To Six European Countries
29/10/2026 12:44
BRIEF-Nuvation Bio To Expand Pivotal Phase 3 Sigma Study Of Safusidenib For Idh1-Mutant Glioma To Six European Countries Oct 29 (Reuters) - Nuvation Bio Inc. NUVB.N:
NUVATION BIO TO EXPAND PIVOTAL PHASE 3 SIGMA STUDY OF SAFUSIDENIB FOR IDH1-MUTANT GLIOMA TO SIX EUROPEAN COUNTRIES
Source text: ID:nPn8PYP8da
Further company coverage: NUVB.N
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Nuvation Bio
See all newsBrief: Nuvation Bio To Expand Pivotal Phase 3 Sigma Study Of Safusidenib For Idh1-Mutant Glioma To Six European Countries
Brief: Nuvation Bio To Report Third Quarter 2026 Financial Results And Provide Business Update On November 4, 2026
U.S. RESEARCH ROUNDUP-Everpure, Marvell Technology, Okta
Nuvation Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Nuvation Bio Q2 revenue beats estimates on IBTROZI growth